Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9163949 | 0.81 | CES1 (0.50) | KLK7CNR2CNR1CRHBPCRHR2 | |
| SCHEMBL5528156 | 0.78 | ALDH1A1 (0.43) | KLK7CNR2CNR1CRHBPCRHR2 | |
| SCHEMBL942923 | 0.76 | ALDH1A1 (0.56) | KLK7CES2CES1MEN1KMT2A | |
| SCHEMBL11095898 | 0.74 | CNR2 (0.44) | KLK7CNR2CNR1CRHBPCRHR2 | |
| SCHEMBL7441943 | 0.74 | NPSR1 (0.45) | KLK7CNR2CNR1CRHBPCRHR2 | |
| SCHEMBL5526156 | 0.74 | CRHBP (0.39) | KLK7CNR2CNR1CRHBPCRHR2 | |
| SCHEMBL7599647 | 0.73 | KMT2A (0.51) | CNR2CRHBPCRHR2CES2CES1 | |
| SCHEMBL7441937 | 0.73 | NPSR1 (0.44) | KLK7CNR2CNR1CRHBPCRHR2 | |
| SCHEMBL9165878 | 0.73 | CES2 (0.46) | KLK7CNR2CNR1CRHBPCRHR2 | |
| SCHEMBL28577864 | 0.70 | CES1 (0.54) | CNR2CNR1CES2CES1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070055081-A1 | Processes for production of alpha-aminooxyketones and alpha-hydroxyketones | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1717221-A1 | PROCESSES FOR PRODUCTION OF ALPHA-AMINOOXYKETONES AND ALPHA-HYDROXYKETONES | Japan Science and Technology Agency (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055081-A1 | Processes for production of alpha-aminooxyketones and alpha-hydroxyketones | KHK, HCCS, XDH | KLK7 163/4885CNR2 4600/4885EPHX2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.